Conformal radiotherapy for unresectable retroperitoneal soft tissue sarcoma.

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Local tumor control is a significant challenge in treating retroperitoneal soft tissue sarcoma.
• Aggressive surgical resection is the primary treatment but is only feasible for a minority of patients.
• Conventional radiotherapy offers limited control for unresectable cases.

Purpose of the Study:

• To evaluate the efficacy of dynamic, 3-D conformal pion radiotherapy for unresectable retroperitoneal soft tissue sarcoma.
• To assess local tumor control and survival rates following pion irradiation.
• To determine the feasibility and morbidity of subsequent surgical interventions.

Main Methods:

• Twenty-one patients with unresectable retroperitoneal soft tissue sarcoma received high-dose pion radiotherapy (≥30 Gy).
• Treatment involved 20 fractions with fraction sizes of 150 or 165 cGy.
• Follow-up ranged from 13-74 months, with subsequent laparotomies performed in nine patients.

Main Results:

• The actuarial five-year local tumor control rate was 60%, with 33% actuarial five-year survival.
• Fifteen patients (71%) were alive at follow-up.
• Post-irradiation laparotomy and resection in five patients showed no increased morbidity, with three complete resections.

Conclusions:

• Dynamic, 3-D conformal pion radiotherapy can achieve significant local tumor control in unresectable retroperitoneal soft tissue sarcoma.
• Preoperative radiotherapy may offer advantages in improving resectability and patient outcomes.
• Pion radiotherapy is a viable option for managing challenging retroperitoneal sarcomas, with acceptable morbidity for subsequent surgeries.